
Alessandro (Ale) Pocai
63 posts

Alessandro (Ale) Pocai
@alee5z
Sr Director @J&J | Scientific Strategy & Innovation




Oral semaglutide demonstrates CV benefits and reduces MACE in people with #T2D on top of standard of care, including use of SGLT-2 inhibitors in the SOUL trial ahajournals.org/doi/10.1161/CI… #ACC2025



The SOUL CVOT with oral semaglutide #T2D 14% reduction in MACE. The mean follow-up was 47.5 months; NNT over 3 yrs=50; 2.95 kg placebo-subtracted #weightloss 26.9% baseline use of SGLT2i #CVD #ACC2025 nejm.org/doi/full/10.10…

















We have entered a strategic research collaboration with @JNJInnovMed to jointly discover and optimize small molecule medicines, combining our expertise to unlock difficult-to-drug targets. #DrugDiscovery #DataScience #AI #ML For more: odysseytx.com/odyssey-therap…



